Journal article

Randomized, placebo-controlled trial of bupropion for the treatment of methamphetamine dependence

Steven Shoptaw, Keith G Heinzerling, Erin Rotheram-Fuller, Trevor Steward, Jason Wang, Aimee-Noelle Swanson, Richard De La Garza, Tom Newton, Walter Ling

DRUG AND ALCOHOL DEPENDENCE | ELSEVIER IRELAND LTD | Published : 2008

Abstract

OBJECTIVE: To compare bupropion to placebo for reducing methamphetamine (MA) use, increasing retention, and reducing the severity of depressive symptoms and MA-cravings. A secondary objective compared bupropion to placebo for reducing cigarette smoking among MA dependent participants. METHODS: Following a 2-week, non-medication baseline screening period, 73 treatment-seeking MA dependent participants were randomly assigned to bupropion sustained release (150 mg twice daily; N=36) or placebo (twice daily; N=37) for 12-weeks under double-blind conditions. Participants attended clinic thrice weekly to provide urine samples analyzed for MA-metabolite, to complete research measures and assessment..

View full abstract